-+ 0.00%
-+ 0.00%
-+ 0.00%

LUCID CAPITAL MARKETS Initiates Coverage On NextCure with Buy Rating, Announces Price Target of $25

Benzinga·05/11/2026 19:17:23
Listen to the news
LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on NextCure (NASDAQ:NXTC) with a Buy rating and announces Price Target of $25.